Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 205

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 205
---
 forms a part and are incorporated in this prospectus by reference.

June 2030 Warrants

As of August 31, 2025, we had 2,260,000 June 2030 Warrants outstanding. Each warrant is exercisable for one common share at an exercise price of $3.10. The June 2030 Warrants were issued on June 2, 2025 in connection with our May 2025 Unit Offering and are exercisable at any time for a period of five years following the date of issuance, expiring on or prior to 5:00 pm ET on June 3, 2030.

The number of June 2030 Warrants outstanding, and the exercise price of those securities, will be adjusted proportionately in the event of a consolidation or share split of our common shares, a recapitalization or reclassification of our common shares, payment of dividends or distributions in common shares to our common share holders, or similar transactions. In the event that the Company effects a rights offering to its common share holders or a pro rata distribution of its assets among its common share holders, then the holders of the June 2030 Warrants will have the right to participate in such distribution and rights offering to the extent of their pro rata share of the Company's outstanding common shares assuming they owned the number of common shares issuable upon the exercise of their June 2030 Warrants. In the event of a "Fundamental Transaction" by the Company, such as a merger or consolidation of it with another company, the sale or other disposition of all or substantially all of the Company's assets in one or a series of related transactions, a purchase offer, tender offer or exchange offer, or any reclassification, reorganization or recapitalization of the common shares, then the June 2030 Warrant holders will have the right to receive, for each common share issuable upon the exercise of a June 2030 Warrants, at the option of the holder, the number of common shares of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration payable as a result of the Fundamental Transaction, that would have been issued or conveyed to the June 2030 Warrant holder had the holder exercised the June 2030 Warrant immediately preceding the closing of the Fundamental Transaction.

<div align='center'>140

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.

PURSUANT TO 17 C.F